Table 1.

Patient characteristics at MTT initiation.

Characteristics		Everolimus group	Sunitinib group	P value
Total number of patients (n = 92)		No of patients (n = 73)	No of patients (n = 19)
Gender	Male Female	46 27	12 7	0.991
Age: mean ± s.d.		58 ± 14	56 ± 15	0.680
Inheritance	Sporadic Familial (MEN1)	67 6	17 2	0.751
Primary tumour site	Pancreas Small intestinal Lung/thymus Unknown primary (UPO)	42 19 7 5	15 2 0 2	0.188
Liver Tumour load	No liver metastases <5 unilobar liver metastases 5–10 unilobar liver metastases and/or bilobar liver metastases >10 liver metastases or diffuse liver metastases	7 11 6 49	1 1 1 16	0.526
KI67 group	KI67 <3% KI67 3–20% KI67 >20%	13 48 5	2 15 1	0.645
Secretory status	Yes No	29 44	5 14	0.281
Prior Surgery	Yes No	40 33	12 7	0.512
SRS or 68Ga-PET	Positive Negative Unknown	60 6 7	14 3 2	0.597
FDG-PET	FDG-PET positive FDG-PET negative Unknown	8 10 55	4 3 12	0.465
Previous treatment	SSA or naive Pre-treated with chemotherapy	56 17	9 10	0.012
Concomitant SSA	Yes No	70 3	16 3	0.100
CCI	0 1 2 3	52 14 6 1	13 6 0 0	0.406

Pearson chi-square test and Fisher’s exact test were conducted as appropriate.

CCI, Charlson Comorbidity Index; FDG-PET, fluoro-deoxyglucose positron emission tomography; Ga, Gallium; MEN1, multiple endocrine neoplasia type 1; MTT, molecular targeted therapy; SSA, somatostatin analogue; SRS, somatostatin receptor scintigraphy.